Vasa Therapeutics Closes Seed Funding
Summary
Vasa Therapeutics, an Encinitas, CA-based preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, closed a Seed funding of $6M supplemented by $2.3M non-dilutive grant funding. The round was led by Orphinic Scientific and included participation from private investments funds NuFund Venture Group, SeedFolio, and others. Led by CEO Artur Plonowski, MD, PhD, CEO, Vasa is a biopharmaceutical company developing therapeutics that target pathophysiology of cardiovascular aging: • VS-041 is a personalized medicine-based treatment of HFpEF. VS-041 shows a reduction of cardiac fibrosis in preclinical HFpEF model and inhibits release of signaling collagen fragments, such as PRO-C6, that mediate fibroinflammatory responses and are biomarkers of worse outcomes in HFpEF patients. • Long acting apelin peptide analogs for combination treatment with incretins in obesity patients at risk for skeletal muscle loss or cardiovascular disease.